Passage BIO (PASG) Retained Earnings (2019 - 2026)
Passage BIO (PASG) posted quarterly Retained Earnings of -$712.3 million for Q1 2026, down 5.59% year-over-year from -$754.5 million in Q1 2025, and down 1.07% quarter-over-quarter from -$704.8 million in Q4 2025.
Passage BIO (PASG) Retained Earnings (2019 - 2026) Analysis & Trends
Passage BIO's Retained Earnings history runs 8 years deep, the most recent figure standing at -$712.3 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 5.59% year-over-year to -$712.3 million; the TTM figure through Mar 2026 stood at -$712.3 million (down 5.59% YoY), while the FY2025 annual figure was -$704.8 million, down 197.82% from the prior year.
- Retained Earnings for Q1 2026 stood at -$712.3 million, down from -$704.8 million in the prior quarter.
- The five-year high for Retained Earnings was $720.5 million in Q4 2024, with the low at -$712.3 million in Q1 2026.
- The 5-year median for Retained Earnings is -$340000.0 (2023), against an average of $18.2 million.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings jumped 374677.08% in 2024, then tumbled 1020795.52% in 2025.
- Passage BIO's Retained Earnings stood at $694.7 million in 2022, then gained by 1.59% to $705.8 million in 2023, then gained by 2.08% to $720.5 million in 2024, then sank by 197.82% to -$704.8 million in 2025, then retreated by 1.07% to -$712.3 million in 2026.
- Business Quant data shows PASG's Retained Earnings at -$712.3 million in Q1 2026, -$704.8 million in Q4 2025, and -$691.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 4.38 Bn |
| 10 | Passage BIO | 13.96 Mn | 13.96 Mn | - | 724.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 724.59 Mn |
| Mar 31, 2026 | -712.32 Mn |
| Dec 31, 2025 | -704.76 Mn |
| Sep 30, 2025 | -691.80 Mn |
| Jun 30, 2025 | -684.00 Mn |
| Mar 31, 2025 | -674.60 Mn |
| Dec 31, 2024 | 720.49 Mn |
| Sep 30, 2024 | 719.19 Mn |
| Jun 30, 2024 | -67,000.00 |
| Mar 31, 2024 | 716.13 Mn |
| Dec 31, 2023 | 705.79 Mn |
| Sep 30, 2023 | -192,000.00 |
| Jun 30, 2023 | -340,000.00 |
| Mar 31, 2023 | -427,000.00 |
| Dec 31, 2022 | 694.73 Mn |
| Sep 30, 2022 | -465.34 Mn |
| Jun 30, 2022 | 688.25 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -356.28 Mn |
| Sep 30, 2021 | -305.13 Mn |